Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effect of Azasite on Corneal Surface Irregularity in Subjects With Meibomian Gland Dysfunction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Azithromycin (Primary)
- Indications Corneal disorders; Meibomian gland dysfunction
- Focus Therapeutic Use
- 27 Sep 2016 Status changed from discontinued to withdrawn prior to enrolment due to lack of enrollment.
- 05 May 2015 New trial record